Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Keywords

Medicine, Paclitaxel, Bevacizumab, Metastatic breast cancer, Oncology

References

• Interim analyses: the repeated confidence interval approachChristopher Jennison, Bruce W. Turnbull — 1989
• Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubulesFrancesco Bausi — 2006
• Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy ApproachesRobert S. Kerbel, Joanne Yu, Jennifer M. Tran — 2004
• Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesMichele Relf, S LeJeune, Prudence A. E. Scott — 1997
• Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.Marianne J. Brady, David Cella, Fei Mo — 1997
• Proportional hazards tests and diagnostics based on weighted residualsPatricia M. Grambsch, Terry M. Therneau — 1994
• Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.Mark D. Pegram, D Reese — 2002
• The biology of vascular endothelial growth factor.Napoleone Ferrara, Terri Davis-Smyth — 1997
• The biology of VEGF and its receptorsNapoleone Ferrara, Hans‐Peter Gerber, Jennifer LeCouter — 2003
• Tumor metastasis: mechanistic insights and clinical challengesPatricia S. Steeg — 2006
• Direct-to-patient BRCA1 testing: the Twoj Styl experienceJacek Gronwald, Tomasz Huzarski, Tomasz Byrski — 2006
• A multiple testing procedure for clinical trials.Peter C. O’Brien, Thomas R. Fleming — 1979
• The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era.Kathy D. Miller, Chris Sweeney, George W. Sledge — 2003
• Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.Harold F. Dvorak — 2002
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.Kathy D. Miller, Linnea Chap, Frankie A. Holmes — 2005
• An alternative parameterization of the general linear mixture model for longitudinal data with non‐ignorable drop‐outsGarrett M. Fitzmaurice, Nan M. Laird, Lucy Shneyer — 2001
• Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux.Danièle Brouty‐Boyé, Despina S. Kolonias, C. Wu — 1995
• The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.Christopher J. Sweeney, Kathy D. Miller, Sean E. Sissons — 2001
• New guidelines to evaluate the response to treatment in solid tumorsPatrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer — 2000
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.Alan Sandler, Robert J. Gray, Michael C. Perry — 2006

Cited by

• Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled BevacizumabYin Zhang, Hao Hong, Jonathan W. Engle — 2011
• Therapeutic options in the management of metastatic breast cancer.Michaela J. Higgins, Antonio C. Wolff — 2008
• Compounds in clinical Phase III and beyond.Torsten Keßler, Michael Bayer, Christian Schwöppe — 2010
• Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined.Thomas J. Kehle, James R. Barclay — 2009
• Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.喜雄 大竹 — 2009
• Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.Авдеев Сергей Михайлович, Соснин Эдуард Анатольевич, Смирнов Александр Александрович — 2010
• Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.Antonio Álvarez Cañibano — 2010
• A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?Ayham Arab Oghli, Helmut Steveling — 2010
• Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.文孝 石田, 孝子 仁科, 孝次 村越 — 2010
• Past, present and future of targeted therapy in solid tumors.Laurent Levassort — 2010
• Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancerKate Goddard — 2010
• Primary systemic chemotherapy for inflammatory breast cancerLouis J. Galloway — 2010
• INTRAVITREAL BEVACIZUMAB DURING PREGNANCYNora Lorentia Febirauqa — 2010
• Intrinsic Resistance to Chemotherapy in Breast Cancer純 佐々木, 文夫 田中, 雅之 大道 — 2010
• Bevacizumab and breast cancer: the E2100 outlier.R.V. Manaois, Arturo Morales, Riza Abilgos-Ramos — 2010
• Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.Kazuki Taketoshi — 2011
• Review on clinical trials of targeted treatments in malignant mesotheliomaM. N. I. Magdoub, A. E. Shehata, E. O. Fayed — 2011
• [Avastin in the treatment of breast cancer].Б. В. Заводовский — 2011
• A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.ひとみ 篠藤, 理恵 鼻岡, 和弘 阿部 — 2011
• Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility StudyRichard Alvin Merriman — 2008

Related papers

• Intracranial hemorrhage in patients treated with bevacizumab：Report of two casesTakeshi, Nishimura, Makoto Makoto — 2011
• Bevacizumab improves the delivery and efficacy of paclitaxelMieko Yanagisawa, Keigo Yorozu, Mitsue Kurasawa — 2010
• Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trialsAntonis Valachis, Nikolaos P. Polyzos, Nikolaos A. Patsopoulos — 2010
• Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?Alberto J. Montero, Mauricio A. Escobar, Gilberto Lopes — 2012
• Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?Punam Rana, Kathleen I. Pritchard, Robert S. Kerbel — 2017
• First-line Treatment of Metastatic Breast Cancer: Focus on Bevacizumab:Teruhiko Fujii, Hiroki Takahashi, Roka Namoto Matsubayashi — 2009
• Review of bevacizumab in the treatment of metastatic breast cancerVolker Heinemann — 2008
• Bevacizumab in metastatic breast cancer: when may it be used?Shari Goldfarb, Clifford A. Hudis, Maura N. Dickler — 2011
• PCN96 A UK COST-UTILITY ANALYSIS OF PACLITAXEL ALBUMIN COMPARED TO SOLVENT-BASED PACLITAXEL MONOTHERAPY AND DOCETAXEL MONOTHERAPY FOR PRETREATED METASTATIC BREAST CANCER (MBC)EJ McLeod, Alex M. Lloyd, Yevgeniy Samyshkin — 2010